A new clinical study published in the Journal of Cosmetic Dermatology revealed in a head-to-head trial that intralesional triamcinolone led to significantly greater hair regrowth and patient satisfaction when compared to methotrexate in localized alopecia areata (AA) treatment.

Alopecia areata affects millions worldwide, manifesting as sudden hair loss in small patches or, in severe cases, across the entire scalp. Corticosteroid injections, particularly with triamcinolone acetonide (TrA), are often the frontline treatment, while methotrexate (MTX), which is a drug with immune-suppressing properties, has been investigated as an alternative. However, few studies have directly compared their effectiveness.

In this trial, a total of 40 patients with localized AA were divided into a group r

See Full Page